# A Trial Evaluating the Blood Glucose-lowering Effect of NN1250 in Subjects With Type 2 Diabetes

> **NCT01154881** · PHASE1 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 49 (actual)

## Conditions studied

- Diabetes
- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** insulin degludec

## Key facts

- **NCT ID:** NCT01154881
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-06
- **Primary completion:** 2010-11
- **Final completion:** 2010-11
- **Target enrollment:** 49 (ACTUAL)
- **Last updated:** 2017-01-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01154881

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01154881, "A Trial Evaluating the Blood Glucose-lowering Effect of NN1250 in Subjects With Type 2 Diabetes". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01154881. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*